Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9X7O

Lansoprazole derivative in complex with CRM1-Ran-RanBP1

This is a non-PDB format compatible entry.
Summary for 9X7O
Entry DOI10.2210/pdb9x7o/pdb
DescriptorGTP-binding nuclear protein Ran, [1-(1H-benzimidazol-2-yl)-3-methyl-4-[2,2,2-tris(fluoranyl)ethoxy]pyridin-1-ium-2-yl]methanethiol, Ran-specific GTPase-activating protein 1, ... (11 entities in total)
Functional Keywordsnuclear export inhibitor, transport protein
Biological sourceHomo sapiens (human)
More
Total number of polymer chains3
Total formula weight157791.88
Authors
Sun, Q.,Luo, Y. (deposition date: 2025-10-17, release date: 2026-06-03, Last modification date: 2026-06-10)
Primary citationLuo, Y.,Yan, Q.,Huang, B.,Luo, Y.,Yu, T.,Zhou, Q.,Wang, C.,Tang, M.,Sun, Q.
Mechanism of CRM1 Inhibition by Lansoprazole and Its Synergy with Cisplatin in Gastric Cancer.
J.Med.Chem., 69:11705-11719, 2026
Cited by
PubMed Abstract: CRM1 (Chromosome Region Maintenance 1, also known as Exportin-1 or XPO1) is a key nuclear export factor that exports and inactivates tumor suppressor proteins in cancer. Here, we report that the proton pump inhibitor lansoprazole, upon acid activation, is converted into a CRM1 inhibitor in vitro. The active component is a positively charged molecule that binds noncovalently to the nuclear export signal (NES) groove of CRM1, as revealed by biochemical studies and a 2.0 Å cocrystal structure. Interestingly, lansoprazole undergoes spontaneous activation in cells, thereby inhibiting nuclear export to a similar extent as its preacid-activated form. Since the compound is susceptible to inhibition by glutathione (GSH), we designed a combination strategy where cisplatin, by depleting GSH, synergistically enhanced CRM1 inhibition. This combination demonstrated antitumor synergy in a gastric cancer xenograft model without increasing toxicity. Our work presents a novel CRM1 inhibitor and a chemosensitization strategy for gastric cancer.
PubMed: 42134807
DOI: 10.1021/acs.jmedchem.6c01114
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2 Å)
Structure validation

254917

PDB entries from 2026-06-10

PDB statisticsPDBj update infoContact PDBjnumon